

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

NEOSE TECHNOLOGIES INC
Form 10-Q
April 29, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2002.

OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 0-27718

NEOSE TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware

13-3549286

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

102 Witmer Road
Horsham, Pennsylvania

19044

(Address of principal executive offices)

(Zip Code)

(215) 315-9000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes [X] No []

Indicate the number of shares outstanding of each of the issuer's

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

classes of common stock, as of the latest practicable date: 14,272,671 shares of common stock, \$.01 par value, were outstanding as of April 15, 2002.

NEOSE TECHNOLOGIES, INC.
(a development-stage company)

INDEX

	Page

PART I. FINANCIAL INFORMATION: -----	
Item 1. Financial Statements	
Consolidated Balance Sheets (unaudited) at December 31, 2001 and March 31, 2002	3
Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2001 and 2002, and for the period from inception through March 31, 2002	4
Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2001 and 2002, and for the period from inception through March 31, 2002	5
Notes to Unaudited Consolidated Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	7
Item 3. Quantitative and Qualitative Disclosure About Market Risk	14
PART II. OTHER INFORMATION: -----	
Item 6. Exhibits and Reports on Form 8-K	14
SIGNATURES	15

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements

NEOSE TECHNOLOGIES, INC.
(a development-stage company)

CONSOLIDATED BALANCE SHEETS

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

(unaudited)
(in thousands, except per share amounts)

Assets	December 31, 2001

Current assets:	
Cash and cash equivalents	\$ 76,245
Restricted funds	902
Prepaid expenses and other current assets	1,635

Total current assets	78,782
Property and equipment, net	22,649
Other assets, net	4,355

Total assets	\$105,786
	=====
Liabilities and Stockholders' Equity	
Current liabilities:	
Current portion of long-term debt	\$1,100
Accounts payable	719
Accrued compensation	855
Accrued expenses	2,844
Deferred revenue	1,222

Total current liabilities	6,740
Long-term debt	5,100

Total liabilities	11,840

Stockholders' equity:	
Preferred stock, \$.01 par value, 5,000 shares authorized, none issued	--
Common stock, \$.01 par value, 30,000 shares authorized; 14,089 and 14,173 shares issued; 14,083 and 14,167 shares outstanding	141
Additional paid-in capital	176,124
Treasury stock, 6 shares at cost	(175)
Deferred compensation	(503)
Deficit accumulated during the development-stage	(81,641)

Total stockholders' equity	93,946

Total liabilities and stockholders' equity	\$105,786
	=====

The accompanying notes are an integral part of these consolidated financial statements.

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

NEOSE TECHNOLOGIES, INC.
(a development-stage company)

CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)

	Three months ended March 31,	
	----- 2001 -----	2002 -----
Revenue from collaborative agreements	\$ 312	\$ 771
Operating expenses:		
Research and development	3,167	3,711
Marketing, general and administrative	1,666	2,611
Severance charges	--	2,433
	-----	-----
Total operating expenses	4,833	8,755
	-----	-----
Operating loss	(4,521)	(7,984)
Gain on sale of marketable security	--	--
Interest income	1,321	429
Interest expense	(99)	(40)
	-----	-----
Net loss	\$ (3,299)	\$ (7,595)
	=====	=====
Basic and diluted net loss per share	\$ (0.24)	\$ (0.54)
	=====	=====
Basic and diluted weighted-average shares outstanding	14,007	14,120
	=====	=====

The accompanying notes are an integral part of these consolidated financial statements.

4

NEOSE TECHNOLOGIES, INC.
(a development-stage company)

CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)

	Three months ended March 31,	
	----- 2001 -----	2002 -----

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

Cash flows from operating activities:		
Net loss	\$ (3,299)	\$ (7,595)
Adjustments to reconcile net loss to cash used in operating activities:		
Depreciation and amortization	566	665
Non-cash compensation	(112)	1,560
Common stock issued for non-cash and other charges	-	-
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	(500)	203
Accounts payable	(16)	(41)
Accrued compensation	(267)	301
Accrued expenses	(232)	(1,984)
Deferred revenue	(42)	(104)
	-----	-----
Net cash used in operating activities	(3,902)	(6,995)
	-----	-----
Cash flows from investing activities:		
Purchases of property and equipment	(288)	(3,995)
Proceeds from sale-leaseback of equipment	-	-
Purchases of marketable securities	(48,142)	-
Proceeds from sales of marketable securities	-	-
Proceeds from maturities of and other changes in marketable securities	27,477	-
Purchase of acquired technology	-	-
Investment in equity securities	-	-
Restricted cash related to acquired technology	-	-
	-----	-----
Net cash used in investing activities	(20,953)	(3,995)
	-----	-----
Cash flows from financing activities:		
Proceeds from issuance of debt	-	-
Repayment of debt	-	-
Restricted cash related to debt	(281)	(278)
Proceeds from issuance of preferred stock, net	-	-
Proceeds from issuance of common stock, net	-	-
Proceeds from exercise of stock options and warrants	286	798
Acquisition of treasury stock	-	-
Dividends paid	-	-
	-----	-----
Net cash provided by financing activities	5	520
	-----	-----
Net increase (decrease) in cash and cash equivalents	(24,850)	(10,470)
Cash and cash equivalents, beginning of period	66,989	76,245
	-----	-----
Cash and cash equivalents, end of period	\$42,139	\$65,775
	=====	=====
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 107	\$ 30
	=====	=====
Non-cash investing activities:		
Accrued property & equipment	\$ -	\$ -
	=====	=====
Non-cash financing activities:		
Issuance of common stock for dividends	\$ -	\$ -
	=====	=====
Issuance of common stock to employees in lieu of cash compensation	\$ -	\$ -
	=====	=====

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

The accompanying notes are an integral part
of these consolidated financial statements

5

NEOSE TECHNOLOGIES, INC.
(a development-stage company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1. Basis of Presentation

We have used generally accepted accounting principles for interim financial information to prepare unaudited consolidated financial statements:

- o As of March 31, 2002;
- o For the three months ended March 31, 2001 and 2002; and
- o For the period from inception (January 17, 1989) to March 31, 2002.

Our consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In our opinion, the unaudited information includes all the normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations, and cash flows for the periods presented. You should not base your estimate of our results of operations for 2002 solely on our results of operations for the three months ended March 31, 2002. You should read these consolidated financial statements in combination with:

- o The other Notes in this section;
- o "Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing in the following section; and
- o The Consolidated Financial Statements, including the Notes to the Consolidated Financial Statements, included in our Annual Report on Form 10-K for the year ended December 31, 2001.

2. Severance Charges

In March 2002, we entered into a Separation and Consulting Agreement with Stephen A. Roth, Ph.D., who was the Chief Executive Officer of the Company. Under this agreement, we agreed to provide health insurance benefits to Dr. Roth and to pay him \$39,622 per month for twelve months. On or before the first anniversary of the agreement, Dr. Roth may agree to extend his non-competition and non-solicitation commitments for two additional years by entering into a separate non-competition agreement. If he does so, the Company will continue his health insurance benefits for six additional months, extend the \$39,622 monthly payments for 24 additional months and, for purposes of stock option vesting and exercisability, treat Dr. Roth as remaining in service to the Company until the third anniversary of his resignation as Chief Executive Officer of the Company (or until the end of his service as a director, if later). We have recognized \$0.3 million in severance charges related to this agreement during the three months ended March 31, 2002, and the remaining payment of \$0.2 million will be recognized over the one-year term of the agreement.

In January 2002, we entered into a Retirement Agreement with Edward J. McGuire, Ph.D., Vice President, Research and Development. Following Dr. McGuire's retirement, he will receive payments through 2006, including \$87,500 in 2002, \$125,000 in 2003, and \$100,000 in each of 2004, 2005, and 2006. We will continue to provide Dr. McGuire health insurance benefits through December 31,

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

2003. We also agreed to extend the period of time during which Dr. McGuire may exercise his stock options subsequent to his retirement. We have recognized \$2.1 million in severance charges, of which \$1.6 million is a non-cash expense related to the stock options, for this agreement during the three months ended March 31, 2002.

6

3. Net Loss Per Share

Basic and diluted net loss per share are presented in conformity with Statement of Financial Accounting Standards No. 128, "Earnings Per Share." Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution from the exercise or conversion of securities into common stock. For the three months ended March 31, 2001 and 2002, the effects of the exercise of outstanding stock options and warrants were antidilutive; accordingly, they were excluded from the calculation of diluted earnings per share.

4. Comprehensive Loss

Our comprehensive loss for the three months ended March 31, 2001 and 2002 was approximately \$3.3 million and \$7.6 million, respectively. Comprehensive loss is comprised of net loss and other comprehensive income or loss. For the periods reported, there are no separate sources of other comprehensive income or loss.

5. Reclassifications

Certain prior year amounts have been reclassified to conform to our current year presentation.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

CAUTIONARY STATEMENT PURSUANT TO SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION ACT OF 1995:

This report and the documents incorporated by reference herein contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this report and the documents incorporated herein by reference, the words "anticipate," "believe," "estimate," "may," "expect," "intend," and similar expressions are generally intended to identify forward-looking statements. These forward-looking statements include, among others, the statements in Management's Discussion and Analysis of Financial Condition and Results of Operations about our:

- o expectations for increases in operating expenses;
- o expectations for increases in research and development, and marketing, general and administrative expenses in order to develop products, manufacture commercial quantities of products and commercialize our technology;

7

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

- o expectations for the development, manufacturing, and approval of new products, including our own proprietary products;
- o expectations for incurring additional capital expenditures to expand our manufacturing capabilities;
- o expectations for generating revenue or becoming profitable on a sustained basis;
- o ability to enter into additional collaboration agreements and the ability of our existing collaboration partners to commercialize products incorporating our technologies;
- o estimate of the sufficiency of our existing cash and cash equivalents and investments to finance our operating and capital requirements;
- o expected losses; and
- o expectations for future capital requirements.

Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect our actual results include the following:

- o our ability to commercialize any products or technologies;
- o our ability to maintain our existing collaborative arrangements and enter into new collaborative arrangements;
- o our ability to develop commercial-scale manufacturing facilities;
- o our ability to protect our proprietary products, know-how, and manufacturing processes;
- o unanticipated cash requirements to support current operations or research and development;
- o the timing and extent of funding requirements for the activities of our joint venture with McNeil Nutritionals;
- o our ability to attract and retain key personnel; and
- o general economic conditions.

These and other risks and uncertainties that could affect our actual results are discussed in greater detail in this report and in our other filings with the Securities and Exchange Commission. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, events, levels of activity, performance, or achievements. We do not assume responsibility for the accuracy and completeness of the forward-looking statements other than as required by applicable law.

We do not undertake any duty to update after the date of this report any of the forward-looking statements in this report to conform them to actual results.

You should read this section in combination with the Management's Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2001, included in our Annual Report on Form 10-K and in our 2001 Annual Report to Stockholders.

Overview

Neose develops proprietary technologies for the synthesis and manufacture of complex carbohydrates. Our enzymatic technology platform makes feasible the synthesis and modification of a wide range of complex

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

carbohydrates, which are chains of simple sugar molecules that can be joined together in many different combinations. Our platform enables the production and manipulation of complex carbohydrates either as stand-alone carbohydrate molecules or as carbohydrate structures attached to recombinant therapeutic glycoproteins and glycolipids.

Our GlycoAdvance(TM) program uses our technology to complete the human carbohydrate structures on therapeutic glycoproteins. We are also developing our technology to create novel glycosylation patterns, and to link other molecules, such as polyethylene glycol, to glycoproteins. The application of this technology to proteins potentially results in improved clinical activity and pharmacokinetic profile, enhanced drug development flexibility, stronger and additional patent claims, and yield improvements.

Our GlycoTherapeutics(TM) program uses our technology to enable the development of carbohydrate-based therapeutics. Our GlycoActives(TM) program uses our technology to develop novel carbohydrate food and nutritional ingredients. Neose was initially incorporated in January 1989, and began operations in October 1990. We have incurred operating losses each year. As of March 31, 2002, we had an accumulated deficit of approximately \$89.2 million. We expect additional losses for some time as we expand research and developments efforts, manufacturing scale-up activities, and marketing activities.

Critical Accounting Policies

Our significant accounting policies are described in Note 2 to the consolidated financial statements included in Item 8 of our Form 10-K. We believe our most critical accounting policies relate to recognition of revenue and impairment of long-lived assets.

Revenue Recognition

Revenue from collaborative agreements consists of up-front fees, research and development funding, and milestone payments. We recognize revenues from these agreements consistent with Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements", issued by the Securities and Exchange Commission in December 1999. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. Periodic payments for research and development activities are recognized over the period in which we perform those activities under the terms of each agreement. Revenue resulting from the achievement of milestone events stipulated in the agreements is recognized when the milestone is achieved.

Impairment of Long-Lived Assets

As required by Statement of Financial Accounting Standards No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of" (SFAS 121), we assess the recoverability of any long-lived assets for which an indicator of impairment exists. Specifically, we calculate, and recognize, any impairment losses by comparing the carrying value of these assets to our estimate of the undiscounted future operating cash flows. Although our current and historical operating and cash flows are indicators of impairment, we believe the future cash flows to be received from our long-lived assets will exceed the assets' carrying value. Accordingly, we have not recognized any impairment losses through March 31, 2002.

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

Impairment or Disposal of Long-Lived Assets" (SFAS 144). SFAS 144 replaces SFAS 121 for fiscal years beginning after December 15, 2001. We do not believe SFAS 144 will have a material impact on our consolidated financial position or results of operations.

Liquidity and Capital Resources

We have incurred operating losses each year since our inception. As of March 31, 2002, we had an accumulated deficit of approximately \$89.2 million. We have financed our operations through private and public offerings of our securities, and revenues from our collaborative agreements. We had approximately \$65.8 million in cash and marketable securities as of March 31, 2002, compared to approximately \$76.2 million in cash and marketable securities as of December 31, 2001. The decrease in 2002 was primarily attributable to the use of cash to fund our operating loss and capital expenditures.

During the three months ended March 31, 2002, we invested approximately \$3.9 million in property, equipment, and building improvements. We anticipate capital expenditures during 2002 of approximately \$9.0 million to provide additional cGMP manufacturing capacity in our Horsham, Pennsylvania facility to support our initial anticipated GlycoAdvance requirements, and \$12.0 million to renovate a 40,000 square foot facility, for which we entered into a lease agreement in February 2002. We plan to relocate our non-cGMP research laboratories and corporate office space from our current facility in Horsham, Pennsylvania into the new facility, leaving our current facility available for future expansion of our cGMP manufacturing capacity. We expect to finance the cost of these capital projects by a combination of state economic development programs, private debt financing, and cash from our balance sheet.

In December 2001, we entered into a research, development and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, for the use of our GlycoAdvance technology to develop an improved production system for Wyeth's biopharmaceutical compound, recombinant PSGL-Ig (P-selectin glycoprotein ligand). rPSGL-Ig is being developed to treat inflammation and thrombosis associated with acute coronary syndrome and reperfusion injury. It is currently being evaluated in Phase II clinical trials for heart attack.

Under the agreement, we will receive license, research, and milestone payments that would total up to \$17.0 million if all milestones are met. In addition to ongoing product payments, Neose and Wyeth would also enter into a supply agreement for the long-term supply of GlycoAdvance process reagents for their commercial production needs. In December 2001, we received an upfront-fee of \$1.0 million, of which \$0.9 million is included in deferred revenue in our consolidated balance sheet as of March 31, 2002. We will amortize the up-front fee to revenue over the estimated four-year performance period.

10

In 2001, we announced a stock repurchase program authorizing the repurchase of up to one million shares of common stock in the open market at times and prices that we consider appropriate. During 2001, we purchased 6,000 shares of common stock in the open market for approximately \$0.2 million.

In 1997, we issued, through the Montgomery County (Pennsylvania) Industrial Development Authority, \$9.4 million of taxable and tax-exempt bonds, of which \$6.2 million remained outstanding as of March 31, 2002. The bonds were issued to finance the purchase of our previously leased building and the construction of a pilot-scale manufacturing facility within our building. The bonds are supported by an AA-rated letter of credit, and a reimbursement agreement between our bank and the letter of credit issuer. The interest rate on the bonds will vary weekly, depending on market rates for AA-rated taxable and tax-exempt obligations, respectively. During the quarter ended March 31, 2002,

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

the weighted-average, effective interest rate was 3.4% per year, including letter-of-credit and other fees. The terms of the bond issuance provide for monthly, interest-only payments and a single repayment of principal at the end of the twenty-year life of the bonds. However, under our agreement with our bank, we are making monthly payments to an escrow account to provide for an annual prepayment of principal. As of March 31, 2002, we had restricted funds relating to the bonds of approximately \$1.2 million, which consisted of our monthly payments to an escrow account plus interest earned on the balance of the escrow account.

To provide credit support for this arrangement, we have given a first mortgage on the land, building, improvements, and certain machinery and equipment to our bank. We have also agreed to a covenant to maintain a minimum required cash and short-term investments balance of at least two times the current loan balance. At March 31, 2002, we were required to maintain a cash and short-term investments balance of \$12.4 million. If we fail to comply with this covenant, we are required to deposit with the lender cash collateral up to, but not more than, the loan's unpaid balance.

We believe that our existing cash and short-term investments, expected revenue from collaborations and license arrangements, and interest income should be sufficient to meet our operating and capital requirements through at least 2003, although changes in our collaborative relationships or our business, whether or not initiated by us, may cause us to deplete our cash and short-term investments sooner than the above estimate. The timing and amount of our future capital requirements and the adequacy of available funds will depend on many factors, including if or when any products manufactured using our technology are commercialized.

Joint Venture with McNeil Nutritionals

We have a joint venture with McNeil Nutritionals. We account for our investment in the joint venture under the equity method, under which we recognize our share of the income and losses of the joint venture. In 1999, we reduced the carrying value of our initial investment in the joint venture of approximately \$0.4 million to zero to reflect our share of the joint venture's losses. We recorded this amount as research and development expense in our consolidated statements of operations. We will record our share of post-1999 losses of the joint venture, however, only to the extent of our actual or committed investment in the joint venture.

11

The joint venture developed a process for making fructooligosaccharides and constructed a pilot facility in Athens, Georgia. In 2001, the joint venture closed the pilot facility as it shifted focus to a second generation bulking agent. The joint venture is exploring establishing a manufacturing arrangement with a third party to produce these bulking agents.

During the years ended December 31, 2000 and 2001, the joint venture reimbursed Neose approximately \$1.6 million and \$0.8 million, respectively, for the cost of research and development services and supplies provided to the joint venture. There were no such reimbursements during the year ended December 31, 1999. This amount has been reflected as a reduction of research and development expense in our consolidated statements of operations. As of March 31, 2002, the joint venture owed Neose approximately \$0.4 million. This amount is included in prepaid expenses and other current assets in our consolidated balance sheet. We expect to provide significantly fewer research and development services during 2002, thereby significantly reducing our expected reimbursement from the joint venture.

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

If the joint venture becomes profitable, we will recognize our share of the joint venture's profits only after the amount of our capital contributions to the joint venture is equivalent to our share of the joint venture's accumulated losses. As of March 31, 2002, the joint venture had an accumulated loss since inception of approximately \$10.1 million, of which our share, assuming a 50% ownership interest, is approximately \$5.0 million. Until the joint venture is profitable, McNeil Nutritionals is required to fund, as a non-recourse, no-interest loan, all of the joint venture's aggregate capital expenditures in excess of an agreed-upon amount, and all of the joint venture's operating losses. The loan balance would be repayable by the joint venture to McNeil Nutritionals over a seven-year period commencing on the earlier of September 30, 2006 or the date on which Neose attains a 50% ownership interest in the joint venture after having had a lesser ownership interest. In the event of any dissolution of the joint venture, the loan balance would be payable to McNeil Nutritionals before any distribution of assets to us. As of March 31, 2002, the joint venture owed McNeil Nutritionals approximately \$8.4 million.

We may be required to make additional investments in the joint venture to fund capital expenditures. If the joint venture builds additional production facilities, and we wish to have a 50% ownership interest in the joint venture, we are required to invest up to \$8.9 million to fund half of such expenditures. However, we may elect to fund as little as \$1.9 million of the cost of the facilities, so long as our aggregate investments in the joint venture are at least 15% of the joint venture's aggregate capital expenditures. In this case, McNeil Nutritionals will fund the remainder of our half of the joint venture's capital expenditures, and our ownership percentage will be proportionately reduced. We have an option, expiring in September 2006, to return to 50% ownership of the joint venture by reimbursing McNeil Nutritionals for this amount.

Recent Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board finalized Statements of Financial Accounting Standards No. 141, "Business Combinations" (SFAS 141), and No. 142, "Goodwill and Other Intangible Assets" (SFAS 142), which are effective for fiscal years beginning after December 15, 2001. SFAS 141 requires all business combinations initiated after June 30, 2001 to be accounted for using the purchase method. SFAS 142 no longer requires the amortization of goodwill; rather, goodwill will be subject to a periodic assessment for impairment by applying a fair-value-based test. In addition, an acquired

12

intangible asset should be separately recognized if the benefit of the intangible asset is obtained through contractual or other legal rights, or if the intangible asset can be sold, transferred, licensed, rented, or exchanged, regardless of the acquirer's intent to do so. Such acquired intangible assets will be amortized over their useful lives. All of our intangible assets were obtained through contractual rights and have been separately identified and recognized in our balance sheets. These intangibles are being amortized over their estimated useful lives or contractual lives as appropriate. The adoption of SFAS 142 in the first quarter of 2002 did not have a material impact on our consolidated financial position or results of operations.

In October 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets" (SFAS 144). SFAS 144 changes the accounting for long-lived assets by requiring that all long-lived assets be measured at the lower of carrying amount or fair value less cost to sell whether

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

included in reporting continuing operations or in discontinued operations. SFAS 144, which replaces SFAS 121 "Accounting for Impairment of Long-Lived Assets and for Assets to be Disposed of," is effective for fiscal years beginning after December 15, 2001. The adoption of SFAS 144 did not have a material impact on our consolidated financial position or results of operations.

Results of Operations

Revenues

Revenues from collaborative agreements for the three months ended March 31, 2002 increased to \$0.8 million from \$0.3 million for the corresponding period in 2001. The increase is attributable to our agreement with Wyeth Pharmaceuticals, which we entered into in December 2001. We received an up-front payment of \$1.0 million that is being recognized as revenue over the estimated four-year performance period. In addition to the up-front payment, we recognized \$0.4 million in research funding during the quarter ended March 31, 2002 from Wyeth. Our revenues in the first quarter of 2001 were related to our agreement with Bristol-Myers.

Operating Expenses

Research and development expenses for the three months ended March 31, 2002 increased to \$3.7 million from \$3.2 million for the corresponding period in 2001. The increase during the 2002 period was primarily attributable to increases in the number of employees engaged in research and development and expenses related to GlycoAdvance.

Marketing, general and administrative expenses for the three months ended March 31, 2002 increased to \$2.6 million from \$1.7 million for the corresponding period in 2001. The increase during the 2002 period was primarily due to additional business development personnel and expenses related to GlycoAdvance products and services. The Company also incurred greater legal and patent related expenses.

During the three months ended March 31, 2002, we incurred severance charges of \$2.4 million, of which \$1.6 million is a non-cash charge related to stock option modifications for agreements entered into with two of the Company's executive officers. There were no such charges for the three months ended March 31, 2001.

13

Interest Income and Expense

Interest income for the three months ended March 31, 2002 decreased to \$429,000 from \$1,321,000 for the corresponding period in 2001. The decrease was due to lower average cash and marketable securities balances during the 2002 period.

Interest expense for the three months ended March 31, 2002 decreased to \$40,000 from \$99,000 for the corresponding period in 2001. The decrease was due to lower interest rates during the 2002 period.

Net Loss

Our net loss for the three months ended March 31, 2002 increased to \$7.6 million, or \$0.54 per share, from \$3.3 million, or \$0.24 per share, for the corresponding period in 2001.

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

Item 3. Quantitative and Qualitative Disclosure About Market Risk

Our holdings of financial instruments are comprised primarily of government agency securities. All such instruments are classified as securities held to maturity. We seek reasonable assuredness of the safety of principal and market liquidity by investing in rated fixed income securities, while at the same time seeking to achieve a favorable rate of return. Our market risk exposure consists principally of exposure to changes in interest rates. Our holdings are also exposed to the risks of changes in the credit quality of issuers. We typically invest in the shorter-end of the maturity spectrum. At March 31, 2002, our entire investment portfolio was held in money market securities, with no amounts invested in government securities or other notes. The approximate principal amount and weighted-average interest rate per year of our investment portfolio as of March 31, 2002 was \$65.5 million and 1.95%, respectively.

We have exposure to changing interest rates on our taxable and tax-exempt bonds, and we are currently not engaged in hedging activities. Interest on approximately \$6.2 million of outstanding indebtedness is at an interest rate that varies weekly, depending on the market rates for AA-rated taxable and tax-exempt obligations. During the quarter ended March 31, 2002, the weighted-average, effective interest rate was approximately 3.4% per year.

PART II OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

(a) List of Exhibits: None

(b) Report on Form 8-K:

On February 1, 2002, we filed a Current Report on Form 8-K announcing a research, development and license agreement with Wyeth-Ayerst Laboratories.

On April 4, 2002, we filed a Current Report on Form 8-K announcing the appointment of C. Boyd Clarke as president, chief executive officer, and director. The Current Report on Form 8-K was subsequently amended on April 29, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 10-Q

NEOSE TECHNOLOGIES, INC.

Date: April 29, 2002

By: /s/ A. Brian Davis

A. Brian Davis
Principal Financial and
Accounting Officer